Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
1.–5. rezultāts no 100.
51. lappuse
... phosphate Dicalcium phosphate dihydrate Disodium hydrogen phosphate1 Phosphoric acid ' Sodium dihydrogen phosphate Sodium dihydrogen phosphate monohydrate Sodium phosphate , dibasic anhydrous rea- gent ' ( 3 ) Antidiarrheal drug ...
... phosphate Dicalcium phosphate dihydrate Disodium hydrogen phosphate1 Phosphoric acid ' Sodium dihydrogen phosphate Sodium dihydrogen phosphate monohydrate Sodium phosphate , dibasic anhydrous rea- gent ' ( 3 ) Antidiarrheal drug ...
224. lappuse
... phosphate gel when used as part of an antacid combination product and contributing at least 25 percent of the total ... Phosphate - containing active in- gredients : ( 1 ) Aluminum phosphate ; maximum daily dosage limit 8 grams . ( 2 ) ...
... phosphate gel when used as part of an antacid combination product and contributing at least 25 percent of the total ... Phosphate - containing active in- gredients : ( 1 ) Aluminum phosphate ; maximum daily dosage limit 8 grams . ( 2 ) ...
227. lappuse
... phosphate diet to prevent forma- tion of phosphate urinary stones , through the reduction of phosphates in the serum and urine . ' ( 4 ) For products containing aluminum identified in §331.11 ( a ) —Warnings . ( 1 ) Prolonged use of ...
... phosphate diet to prevent forma- tion of phosphate urinary stones , through the reduction of phosphates in the serum and urine . ' ( 4 ) For products containing aluminum identified in §331.11 ( a ) —Warnings . ( 1 ) Prolonged use of ...
271. lappuse
... phosphate fluoride derived from sodium fluoride acidulated with a mixture of sodium phosphate , monobasic , and phosphoric acid to a level of 0.1 molar phosphate ion and a pH of 3.0 to 4.5 and which yields an effective fluoride ion con ...
... phosphate fluoride derived from sodium fluoride acidulated with a mixture of sodium phosphate , monobasic , and phosphoric acid to a level of 0.1 molar phosphate ion and a pH of 3.0 to 4.5 and which yields an effective fluoride ion con ...
273. lappuse
... phosphate fluo- ride solution containing 0.02 percent fluo- ride ion , sodium fluoride 0.05 percent , so- dium fluoride concentrate , and stannous fluoride concentrate identified in § 355.10 ( a ) ( 3 ) ( i ) , ( a ) ( 3 ) ( iv ) , ( a ) ...
... phosphate fluo- ride solution containing 0.02 percent fluo- ride ion , sodium fluoride 0.05 percent , so- dium fluoride concentrate , and stannous fluoride concentrate identified in § 355.10 ( a ) ( 3 ) ( i ) , ( a ) ( 3 ) ( iv ) , ( a ) ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning